Shire Bioequivalence Study Results Of SPD465, Investigational Drug For Adults With ADHD

Thu, 23 Nov 2006 03:00 PM EST

... Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that a single once-daily morning dose of the investigational amphetamine compound SPD465, extended release triple-bead mixed amphetamine salts, designed to reduce symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults for up to 16 [click link for full article] ...